Acute Cognitive Effects of Brain Edge

Completed · Not applicable · Has a placebo group

Conditions studied: Cognitive Health, Mood

In brief

A double-blind placebo-controlled crossover study exploring the cognitive effects of Brain Edge; a supplement consisting of a blend of herbs and amino acids. 50 healthy adult subjects will be evaluated over 3 sessions. Evaluation of cognitive performance will be determined by computer-based software, surveys, and VR headset experiences.

Key facts

Study ID

NCT07018674

Run by

Nature's Sunshine Products, Inc.

People needed

50

Starts

2025-08-20

Expected to finish

2025-11-20

Last updated by the study team

2026-04-13

Who can join

Age: 18 and older, up to 64. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Men, women and non-binary adults, ≥18 and <60 years old
• Generally healthy
• Ability to understand and the willingness to follow the study procedures.
• Willing to maintain a consistent diet (including medications, vitamins and supplements) and lifestyle routine throughout the study.
• Willing to give written informed consent to participate in the study.

You may not qualify if…

• Pregnant or nursing.
• Minors below the age of majority.
• Taking any prescription stimulants or anxiolytics.
• Typical caffeine intake above 250 mg/day.
• Neurological conditions including epilepsy, color blindness, ADD / ADHD, Learning disabilities, or dementia.
• Change in prescription, non-prescription, nutritional supplements and/or medical foods within 7 days prior to Day 1 and for the duration of the study.
• Use of prescriptions medications and/or nonprescription medications for acute and semi-acute medical conditions 30 days prior to Day 1 and for the duration of the study.
• Use of an investigational drug or participation in an investigational study within 30 days prior to Day 1 and for the duration of the study.
• Routine use of high dose caffeine >250mg products within 7 days prior to Day 1 and for the duration of the study.
• Subjects with a history of allergy or intolerance to any ingredient in study product. Specific details of each product will be included in the formal Study Informed Consent.
• Serious, unstable illnesses including hepatic, renal, gastroenterologic, respiratory, endocrinologic, neurologic, immunologic, or hematologic disease.
• Subjects with a current diagnosis or personal history of:
• Any cardiovascular disease including myocardial infarction, angina, cardiovascular surgery, congestive heart failure, cardiac arrhythmias or conduction abnormalities, cerebrovascular accident, transient ischemic attack (TIA), or peripheral vascular disease, deep vein thrombosis or pulmonary embolus.
• Any neurological condition including ADD, ADHD, Epilepsy, Narcolepsy, insomnia, or autism spectrum disorders.
• Any serious mental illness including a history of attempted suicide.
• Use of drugs of abuse (such as marijuana, cocaine, opiates and methamphetamine) 7 days prior to Day 1 and for the duration of the study.
• Inability to comply with study and/or follow-up visits.
• Any concurrent condition (including clinically significant abnormalities in medical history, physical examination, or laboratory evaluations) which, in the opinion of the PI, would preclude safe participation in this study or interfere with compliance.
• Any sound medical, psychiatric and/or social reason which, in the opinion of the PI, would preclude safe participation in this Study or interfere with compliance.
• Co-enrollment in other trials is restricted other than for observational studies. Study staff should be notified of co-enrollment as it may require the approval of the investigator.

Where it is running

• The Hughes Center for Research and Innovation — Lehi, Utah, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.